Herein, NAB815 was found to be effective at sub-bactericidal concentrations in blocking the interactions of Stx2a with human circulating cells and preventing the functional consequences related to HUS pathogenesis, i.e., the formation of white cell/platelet aggregates and the release of Stx2-containing EVs. This evidence concerns the gene STX2 and hemolytic-uremic syndrome.